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Background: Neisseria meningitidis is classified based on its surface polysaccharide 
capsule’s antigenicity into thirteen (13) serogroups. More than 90% of the globally invasive 
meningococcal infections were caused by serogroups, A, B and C. Serogroup A was the 
major cause of meningococcal meningitis epidemics in the African meningitis belt prior 
2010 when a monovalent meningococcal A conjugate vaccine (MenAfriVac) was 
introduced in the region.  
Purpose: This paper aimed to examine a five-year trend of Neisseria meningitidis 
serogroups in the meningitis belt of Ghana. 
Methodology: PCR confirmed laboratory results of all suspected cases of cerebrospinal 
meningitis (CSM) from 2016 to 2020 were obtained from the Tamale Public Health 
Laboratory and the data were subjected to trend analysis using SPSS 
Results: Out of the 395 confirmed Neisseria meningitidis cases, 71.4% and 24.6% were 
serogroups Wand X, respectively. Serogroups; B, C and the NG accounted for 0.5%, 0.5% 
and 3%, respectively. There is a significant upward trend of serogroup X (p=0.01) and 
downward trend of the serogroup W (p=0.01) and serogroup C (p=0.05). The serogroups 
B and C are also showing a downward trend, and the NG serogroups are in the upward 
trajectory. However, the serogroups; B, and NG yearly are insignificant (with p-values; 
0.78, and 0.21, respectively). 
Conclusion: There has been the emergence of serogroup X, a non-vaccine type Neisseria 
meningitidis serogroup, as the predominant Neisseria meningitidis serogroup, and is on the 
upward trajectory since 2016 in the wake of a declining serogroup W after the introduction 
of the meningococcal polysaccharide ACW vaccine following the outbreak of serogroup 
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Bacterial meningitis is a severe acute infection of the fluid surrounding the brain and the 
spinal cord resulting in the inflammation of the meninges that can rapidly result in death. 
Bacterial meningitis can be fatal in about 50% of all cases if treatment is not given. Even 
when early diagnosis is made and adequately treated, about 8-15% of cases result in death, 
usually within 24 and 48 hours after the onset of symptoms1. In Africa, 25% of individuals 
infected could experience neurologic sequelae, including brain damage, hearing loss, and 
learning disabilities despite the treatment with the recommended antibiotics2. According to 
the WHO, meningitis remains a universal public health challenge in countries worldwide 
where cases and outbreaks are highly dreaded, with the global number of deaths, as a result, 
estimated to be 380, 000 annually. The highest outbreaks and deaths as a result of 
meningitis occur in the developing countries3. In the year 2009, an estimated number of 
80,000 suspected cases with 4000 resulting in death were reported in of Africa’s meningitis 
belt which comprises 26 countries in the sub-Saharan region where the death rate resulted 
from the disease the highest1. 
The causative organisms of bacterial meningitis vary by age group. In neonates, a more 
significant number of bacterial meningitis cases result of group B Streptococcus 
agalactiae, Escherichia coli and Listeria monocytogenes. However, most cases of bacterial 
meningitis in children and adults are caused by Streptococcus pneumoniae and Neisseria 
meningitidis 3,4. Although Haemophilus influenzae causes meningitis in all age groups, a 
greater number is usually seen in children under five (5) years of age 5,6.  
Neisseria meningitidis is one of the most common causes of meningitis over the word. 





throughout a large area of the meningitis belt of Africa and outside7. An estimated 500,000 
cases and 50,000 deaths annually worldwide, is associated with Neisseria meningitidis, 
with children and young adults being the most vulnerable, according to the World Health 
Organization (WHO)8. Neisseria meningitidis can be classified based on the antigenicity 
of its surface polysaccharide capsule into thirteen (13) serogroups9. More than 90% of the 
globally invasive meningococcal infections are caused by serogroups, A, B and C. 
Serogroup A meningococci is implicated in a more significant number of the meningitis 
epidemics that occur in the African meningitis belt and China, but rarely in the 
industrialised countries 10,11,12,8,13. Serogroup C is also implicated in the disease outbreak 
and occasional epidemics14,15. Serogroups B and C were responsible for endemic 
meningococcal meningitis with occasional occurrences as a result of serogroups, W135, Y 
and X16,17. However, serogroup W135 also causes endemic diseases in some African 
meningitis belt countries. The serogroup A epidemics in Africa’s  meningitis belt occur in 
a cycle of every 8-12years with each wave following a multi-year gradual increase in 
volume-decrease in volume of cases pattern18. The incidence of meningococcal meningitis, 
just like the other bacterial meningitis is seasonal dependent with peaks in the dry season 
(December-May) and decreases rapidly, even in times of major epidemic with the start of 
the rainy season18,19. 
Although meningococcal meningitis is endemic in various regions across the world, its 
burden is remarkable in 26 countries which make up the “meningitis belt” of sub-Saharan 
Africa, stretching from Senegal in the west to Ethiopia in the eastern part20. Meningococcal 
meningitis is hyperendemic in the region, with the number of incidence cases approaching 
1000 per 100,000 population in the dry season. The annual epidemics in the region is 
broadly distributed across age groups. However, outside of epidemic situations, the highest 
incidence mostly occurs in young children8.  
The majority of meningococcal meningitis within the meningitis belt of the sub-Saharan 
Africa region between 1993 and 2012 was mainly due to serogroup A, the aetiological 





deaths20. Consequently, a monovalent meningococcal A conjugate vaccine (MenAfriVac) 
was developed and prequalified for children and adults aged 1-29years21,22. It was then used 
in a prophylactic vaccination campaign in Burkina Faso, Mali and Niger in 201023. As a 
result of the vaccine introduction, by 2014, there were no cases due to serogroup A in those 
three countries24 and other African countries such Ghana who implemented the vaccine 
programme. However, in the wake of decline of the disease due to serogroup A, serogroup 
W emerged as the predominant aetiological agent being responsible for 55% of confirmed 
cases in 2012 in the region25. Cases due to serogroup C are also in the upward trajectory in 
the sub-Saharan African region. 82.7% of 433 confirmed cases during the outbreak in 
Nigeria from December 2016 to June 2017 were due to serogroup C. It is considered the 
largest outbreak of meningococcal meningitis due to serogroup C in the word26. 
Although meningococcal meningitis incidence has been generally low in Europe, there 
have been some incidence increases over the past decade. The incidence in 2015 was 0.6 
cases per 100,000 population in the European Union, a decline from the 0.7 in 2010. The 
highest number of cases per 100,000 population in 2015 were recorded in Lithuania (1.9), 
Ireland (1.5), the UK (1.4) and Malta (1.2)27. Even though the overall incidence is low, the 
emergence of certain serogroups is cause for worry. For instance, there has been increases 
in meningococcal disease incidence due to clonal complex variant of serogroup W in the 
UK. It accounted for 15% of cases during the 2013-2014 epidemiologic year compared to 
1.8% during the 2008-2009 epidemiologic year28, which affected mainly adults 45years 
and older. Cases, however, were distributed across all age group by 2011-2012. Also, there 
was a concern with the emergence of serogroup C in Italy in 2015 and 2016, with a 
substantial increase in cases (43cases) compared with those reported in 2013 (12) and 2014 
(16). Of the 43 cases, 10 were fatal, and those affected were in the age range of 9 to 82 
years29 
In South America, the annual incidence of meningococcal meningitis varies considerably, 
ranging from less than 0.1 cases per 100,000 population in Bolivia, Cuba, Paraguay and 





known to be responsible for cases in this region with serogroups B and C being responsible 
for most of the cases in the region. The emergence of serogroup W was also the cause of 
outbreaks in several countries within this region30, 31. 
Incidence rates in the Eastern Mediterranean  are highest in Sudan and Yemen, with 13.26 
and 4.74 cases per 100,000 population in 2006 and 2005, respectively. Serogroups A or W 
was responsible for most outbreaks in countries within the region, except for Israel, where 
outbreaks were due to serogroups B or C32. Recent surveillance data from Kuwait indicates 
an incidence rate of 0.5 per 100,000 population, with serogroups W and B being responsible 
for 32% of cases. Serogroup B was responsible for 34% of all cases in children aged 14 
years and below, and serogroup W accounted for 40% of all adult cases. The 1987, 1989 
and 2002 outbreaks in Kuwait were caused by serogroups, A,W and B respectively33. 
The northern part of Ghana lies within Africa’s “meningitis belt” and has been experiencing 
bacterial meningitis outbreaks during the dry seasons, which is usually from December to 
May each year. Although only the northern part of Ghana lies within the African meningitis 
belt, other parts of the country are also at risk of attack, as evidenced in recent outbreaks 
where there were reported cases of serogroup W and C in the Brong Ahafo and the Ashanti 
regions, respectively in 2016. There have also been reported cases in the Central region and 
the Ashanti region during the recent outbreak (December – April 2020). 
In 2010, Ghana recorded a total of 1164 cases of meningitis with 128 deaths, while in 2011 
the country again had 790 cases with 104 deaths. The figure then increased to 956 cases in 
2012 with 90 deaths and decreased to 454 cases and 41 deaths in 2013. There were 477 
cases with 39 deaths and 315 cases with 33 deaths recorded in 2014 and 2015 respectively 
in the country34. A total of 280 and 241 cases were recorded in the 2016 and 2017, 
respectively. The predominant aetiological agent for the total cases of the 2016 and the 






Before 2012, serogroup A meningococcus was responsible for an estimated 80-85% of all 
cases of bacterial meningitis in the meningitis belt of the country (Ghana), with epidemics 
in every 7-14 years. However, after the mass prevention campaign of meningococcal 
serogroup A vaccine in the three northern regions in 2012, there has been a drastic decline 
in the number of cases attributable to it34. There have been zero cases attributable to it in 
recent outbreaks. Just like other countries within the African meningitis belt, the occurrence 
of meningitis outbreaks is now due to other meningococcal serogroups such as the 
serogroups W and X and Streptococcus pneumoniae which have been responsible for most 
of recent outbreaks34-37. 
To minimize the impact of early meningitis outbreaks, Ghana introduced Haemophilus 
influenzae b vaccine in 2002 and the 13-valent pneumococcal conjugate vaccine in 
201238,39. A serogroup A meningococcal conjugate vaccine (MenAfriVac) was introduced 
in 2012 through a mass vaccination campaign to reduce the burden of N. meningitidis 
outbreaks due to serogroup A, which was the most prevalent serogroup at the time. It was 
subsequently incorporated into the routine immunization program in 201638. Despite the 
above interventions however, northern Ghana continued to experience meningitis 
outbreaks resulting from Streptococcus pneumoniae and serogroup W N. meningitidis. 
Given this, a reactive vaccination exercise of meningococcal polysaccharide ACW was 
carried out in the most affected districts in the Upper West region in 201638. 
 
1.2 Problem statement 
 
Despite the numerous interventions put in place by the Ministry of health with the support 
of international partners to reduce the burden of bacterial meningitis in the northern part of 
Ghana, where meningitis is endemic, yearly outbreaks still occur. These outbreaks are 
mainly caused by Streptococcus pneumoniae and Neisseria meningitidis. The Neisseria 
meningitidis cerebrospinal meningitis outbreaks were mainly caused by serogroups A 





the routine immunization program in 2016, and serogroup W, which occasioned the mass 
vaccination campaign of the polysaccharide ACW vaccine in 2016 following its outbreak 
in the Upper West region  the same year. 
With the introduction of rt-PCR at the Tamale Public Health Laboratory in 2012, the 
aetiological agents of bacterial meningitis are being monitored. However, the actual trends 
in the non-groupable and the non-vaccine type serogroups of Neisseria meningitidis and 
the impact of the vaccination programs on the vaccine-preventable serogroups have not 
been adequately highlighted. Therefore, it is imperative that a study of this nature was 
carried out to help establish the trends in the various serogroups of Neisseria meningitidis 
in the meningitis belt of the country to determine whether there was an emerging threat 
from any of either the non-groupable or non-vaccine type Neisseria meningitidis 
serogroups, which had not posed any serious threat in the past, and to establish the influence 




Knowledge of the trends in the various serogroups of Neisseria meningitidis is very crucial 
in informing targeted public health interventions to bring the situation under control. For 
instance, if the trends in the vaccine types serogroups were still found to be taking an 
upwards trajectory, it would inform the need to review the vaccination regimen or improve 
upon the efficacy of the vaccines already available or procure a new vaccine altogether. It 
would also inform the need to undertake molecular study of the circulating serogroup 
strains to determine if the upward trend is due to mutation of the original strain based on 
which vaccines were developed. Again, if the upward trend was found to be in the non-
vaccine type, it would inform the need for the appropriate authorities to start taking the 
necessary steps to educate the population at risk and procure vaccines and anti-microbials 





health threat. Moreover, Ghana can group only six (6) of the thirteen (13) known 
serogroups of Neisseria meningitidis. However, from time to time, some unknown or 
ungroupable serogroups are isolated. If an upward trend is seen in the ungroupable type, it 
would inform the need for further studies to identify those serogroups so that logistics are 
procured for effective surveillance. 
 
1.4 General Objective 
 
The primary objective of the study was to establish the trends in Neisseria meningitidis 
serogroups over five years in the meningitis belt of Ghana from 2016 - 2020 
 
1.5 Specific Objectives 
 
1. To determine the trends in Neisseria meningitidis serogroups in Ghana for the 
past five years. 
2. To determine the trends of the various serogroups of Neisseria meningitidis in the 
reporting regions within the meningitis belt of Ghana 
3. To determine the trends in the various gender and age groups in relation to the 











2.0 LITERATURE REVIEW 
 
2.1 Bacterial Meningitis 
 
Bacterial meningitis is a central nervous system disease caused by some bacterial types. It 
is characterized by inflammation of the membranes (meninges) covering the brain and 
spinal cord. The inflammation of the meninges put pressure on the brain and the spinal 
cord, causing potential life-threatening complications. It is usually preceded by respiratory 
illness or sore throat in adults and children40,41, 42. 
2.1.1 Signs And Symptoms of Bacterial Meningitis 
 
Symptoms in adults and older children usually progress from irritability through confusion, 
drowsiness, and stupor, which may lead to coma. Dehydration is also common. Chills, 
weakness, stiff neck, loss of appetite and photophobia are other symptoms. Later symptoms 
may include paralysis of one side of the body (hemiparesis), loss of hearing, hydrocephalus 
(accumulation of fluid in the brain cavity), and other neurological disorders40,41,43,44,42. 
In infants in the age range of three (3) months and two (2) years, symptoms usually 
includes; fever, vomiting, irritability, convulsion and refusal of feeding. A high-pitched cry 
and bulging fontanel sometimes occur as a result. Cerebral fluid may accumulate inside the 
tough outer brain covering membrane several days after infection. The typical signs of 
meningitis in infants usually include; seizures, persistent fever and an increasing head size. 
Brain abscess or subdural pus accumulation may also occur. Accumulation of water in the 
brain (hydrocephalus), deafness and slowed mental and physical development are possible 





2.1.2 Causes of Bacterial Meningitis 
 
Bacterial meningitis is the most common cause of meningitis. Three (3) bacterial agents 
are responsible for about 80% of bacterial meningitis. These bacterial agents includes; 
Hemophilus influenzae, Streptococcus pneumoniae and Neisseria meningitidis 
(Meningococcus). 
Gram-negative bacteria such as E. coli, Klebsiella or Pseudomonas often cause bacterial 
meningitis in new-born infants. Streptococcus, Staphylococcus aureus, and Listeria 
monocytogenes are other causes of bacterial meningitis. Meningitis due to Hemophilus 
influenza (type B) usually occur in infants over a month old and young children. It normally 
does not occur in adults, however, it can occur in adults with underlining condition such 
head trauma or impaired immunity. Pneumococcal meningitis mostly occur in adults, 
especially those with sinusitus (inflammation of the mucous membranes lining the sinuses 
that open into the nose), mastoiditis (infection of the bone located in the ear), closed head 
injury, and pneumococcal pneumoniae40,41,43,42. 
Bacterial meningitis due to E. coli and Klebsiella-Enterobacter frequently occur after 
central nervous system trauma or surgery. Immune-compromised adults and new-borns 
may also be at risk. Staphylococcal meningitis may also occur after open head trauma, 
neurosurgery and blood poisoning as a result of endocarditis. Listeria meningitis, caused 
by Listeria monocytogenes infection, occurs mostly in new-borns, patients with chronic 
renal failure or adults on immunosuppressive drugs. 
Bacterial agents that cause bacterial meningitis are thought to be carried in the throats of 
approximately 10% of the population. Of all the meningitis causing bacterial, Hemophilus 
influenza type B is the most common and accounts for almost half of all bacterial meningitis 
cases. Meningococcal and Pneumococcal meningitis are said to account for about twenty-





2.2 Meningococcal Meningitis 
 
Meningococcal meningitis is bacterial meningitis resulting from the infection with 
Neisseria meningitidis. Neisseria meningitidis is solely a human Gram-negative diplococci 
which has a great genetic variety46. The genetic plasticity and the phenotypic diversity of 
the meningococcus are the hallmark of its evolution, as it acquired various genes from other 
species of Neisseria and other bacteria, such as Hemophilus spp. The meningococcus is a 
frequent coloniser of the nasopharynx and the oropharynx, however, it can also be found 
in other places such as the oral mucosa, the rectum and the urogenital tract47. The virulence 
of the meningococcus is related to its major outer membrane components, including the 
capsular polysaccharide, outer membrane proteins (pili, porins, Opa, Opc, meningococcal 
iron-acquiring proteins) and lipo-oligosaccharide (endotoxin)47-49. Thirteen (13) serogroups 
of Neisseria meningitidis have been characterized based on the different capsular 
polysaccharide structure, however, only six serogroups (A, B, C, W-135, X and Y) are 
known to cause life-threatening condition49-51. 
 
2.2.1 Global Epidemiology of Meningococcal Meningitis 
 
Globally, the incidence of meningococcal disease changes greatly with respect to 
geographical location. An estimated 500,000-1,200,000 cases of invasive meningococcal 
disease are reported worldwide each year with 50,000-135,000 deaths52, 53. 
In Europe, North America and Australia, the disease incidence is estimated to range 
between 0.3 and 3 cases per 100,000 population54. However, during epidemics, incidence 
is estimated to range between 10-1,000 cases per 100,000 population in the “meningitis 
belt” of sub-Saharan Africa. 
In many regions of the world, the epidemiology of meningococcal disease has substantially 





for invasive meningococcal infection in Europe before and during the World Was I and II. 
Serogroup B has been the prevalent serogroup since 1970 in Europe and 1980 in South 
America. However, epidemic outbreaks due to serogroups W-135 and Y have emerged 
more recently during the XXIst century. Besides the change in the age classes affected by 
invasive meningococcal disease, there has been an increase in the incidence of serogroup 
Y in the elderly and a decreases of serogroup C incidence in adolescents. The trends in the 
epidemiology of invasive meningococcal meningitis has largely remain unchanged in 
Africa, with serogroup A being the most prevalent serogroup. However, serogroups X and 
W-135 have had a significant impact in terms of morbidity and mortality in recent times55. 
The incidence of meningitis caused by serogroup A Neisseria meningitidis in Africa is 
estimated to be 10-20 cases per 100,000 population annually. During epidemic outbreaks 
in the dry seasons, an attack rate is estimated to be more than 1,000 cases per 100, 000 
population. In Latin America however, the incidence ranges between 0.1 cases per 100,000 
population in Mexico to 2 cases per 100,000 population in Brazil, with the predominance 
of serogroups B and C56. The incidence in Australia is estimated to be more than 3 cases 
per 100,000 population. The epidemiological burden of meningococcal infection is not well 
defined in Asia. However, serogroup A is considered the most prevalent. Five (5) 
serogroups (A, B, C, Y and W-135) have been reported in Asia with regional variation57. 
In most countries in America and Europe, there is low level endemicity of meningococcal 
disease. Twenty-nine (29) European countries (27 EU countries and Norway and Iceland), 
in 2011 reported 3,808 confirmed cases of the disease58. The global notification rate has 
been estimated to be 0.77 cases per 100,000 population, with serogroup B being the most 
relevant, accounting for 73.6% of cases, followed by serogroup C, 14.4% and serogroup Y 
making up 8.2%. The disease incidence sustained by serogroup B in Europe accounts for 






The regional or geographical distribution of the main serogroups of the Neisseria 
meningitidis bacteria are shown in figure 1 below. 
 
Figure 1: Global distribution of Neisseria meningitidis serogroups (Source: Journal 
of preventive medicine and hygiene 2015)  
 
2.2.1.1 Epidemiology of Meningococcal Meningitis in Africa 
 
Meningococcal meningitis incidence rate in sub-Saharan Africa greatly exceeds those of 
the other regions in the world60. The disease epidemics in the meningitis belt of Africa 
usually occurs in the dry season from January through to June when the incidence rate can 
go as high as 1,000 cases per 100,000 population. The rate of endemic disease remains 
relatively high at 10-25 cases per 100,000 population in the periods between outbreaks. 
Between 1990 and 2010, the predominant serogroup associated with outbreaks in the region 





polysaccharide conjugate vaccine (MACV) that was administered in 2010 to nearly 100% 
of the population between the ages of 1-29 years in Burkina Faso. The vaccination 
campaign with MACV has since been expanded to a number of countries within the 
meningitis belt of the region with high coverage rate20, 62, 63. Before the introduction MACV 
in 2010, the case fatality ratio (CFR) among countries in the African meningitis belt ranged 
from 4% in Mali to 26% in Benin61. However, since the introduction of the vaccine, the 
overall CFR in surveillance countries has been relatively stable at 8.5%, 9.1% and 9.1% in 
2012, 2013 and 2014, respectively20, 62, 63 . 
With the wide spread use of MACV, there has been a reported overall reduction in epidemic 
activity due to serogroup A among countries in the meningitis belt of the region. During 
2012 meningitis season, Burkina Faso reported more cases of meningitis than in the 2011 
season. This was largely due to the increase in serogroup W cases64. However, in the region 
of Chad where the vaccine was not used, serogroup A was still predominant65, 
demonstrating a shift in serogroups in communities in countries with a successful 
vaccination program. Among meningitis cases in 2012 through to 2014 from which the 
serogroup had been determined, serogroup W had been the most common serogroup now 
with rates, 76%, 72% and 81% in 2012, 2013 and 2014 respectively20, 62, 63. 
There has been a documentation of serogroup X meningococcal meningitis in a number of 
African countries. Outbreaks due serogroup X was reported in Niger, Kenya and Uganda 
in 200666. Although the incidence rate of meningococcal meningitis due serogroup X in the 
region is relatively low, the number of cases, as well as the lack of an effective vaccine, 
calls for the need for continued surveillance of the disease associated with this serogroup 
in the African meningitis belt. 
The figure below illustrates the “Meningitis belt” of the sub-Saharan Africa region showing 






Figure 2 : Countries with frequent epidemics of meningococcal meningitis in sub-
Sahara  Africa (source: World Health Organization. International Travel and 
Health. Geneva, Switzerland: 2012) 
 
2.2.2 Incidence Among Age Groups. 
 
Meningococcal disease incidence is highest in infants under one (1) year  of age and 
remains relatively high until about 5 years of age. Although the incidence tends to decrease 
in older children, it usually spikes later during adolescence and young childhood. Incidence 
again peaks off in older adults. This pattern has been reported both at the regional and 
country levels58, 60, 67-70. The CFR of invasive meningococcal disease is sometimes higher 
in infants than in older children. However, it is routinely highest in adults aged 65 years 





Trends are also observed when examining the prevalence of the various serogroups of 
Neisseria meningitidis. In North America and Europe, serogroup B is the most common 
serogroup associated with invasive meningococcal disease in infants, with incidence also 
routinely spiking during adolescence and young childhood58, 67, 68, 73-75. It has been observed 
recently through surveillance data that serogroup B is the causative agent for at least 70% 
of IMD cases in all age groups up to 24 years of age in Europe58.  
Again, in Europe, a substantial increases in serogroup Y IMD in under 1 year, 1-4 years 
and 25-49 years age group was observed between 2008 and 2011. However, in England the 
highest incidence of serogroup Y was observed in those aged 15-19 years, 45-64 years and 
those 65 years and older. In the United States, serogroup Y IMD is typically seen in older 
individuals, although cases in infants have become more common in recent years58, 76. 
Finally, the most relevant rate of invasive meningococcal disease, particularly in children 
younger than 5 years of age, is related to serogroup B, followed by serogroup C. the 
notification rate of serogroup B infection in children under 1 year of age in 2012 was 
reported to be three-fold higher than those registered in the age group 1-4 years. The highest 
rate of meningococcal infection due to serogroup C has been reported in young adults and 
adults 25-44 years of age77. 
 
2.2.3 Neisseria meningitidis Carriage and the Effects of Vaccine 
 
Neisseria meningitidis is one of the common components of the human nasopharyngeal 
microbiota and its carriage is an important precursor to the development of invasive 
meningococcal disease. While invasive meningococcal disease incidences are highest in 
infants and young children, carriage rates usually peaks in late adolescent or young 
adulthood78, 79. Current studies have shown carriage rate of 4.5% in infants, 23.7% in people 
age 19 years and 7.8% in those aged 50 years in countries such as those in Europe where 





shown carriage rates of Neisseria meningitidis to be 1.8% in infants, 4.9% for those aged 
between 5-14 years and 2.6% for those aged 30 years or older78. In 2012, a study among 
university students in Chile showed a carriage rate of 4%80. In the U.S. states of Georgia 
and Maryland, studies in 2006-2007 showed a relatively low carriage rates of 3.2%-4.0% 
of the bacteria81. This highlights the fact that variation in carriage may be observed in 
different geographical locations. 
The prevention of meningococcal serogroup C carriage and its subsequent herd immunity 
leading to a reduction of invasive meningococcal disease in the unimmunized population 
is an important benefit of immunization programs. Reduction in Neisseria meningitidis 
carriage after immunization appears limited to the polysaccharide-conjugate formulations 
and is hardly seen with polysaccharide only formulation82. The administration of a 
meningococcal A/C polysaccharide vaccine during an outbreak in Brazil had no effect on 
the overall carriage rate. However, meningococcal conjugate C vaccine have routinely 
demonstrated serogroup specific reduction in carriage. The administration of serogroup C 
conjugate vaccine in the United Kingdom, for instance, led to a significant reduction in 
serotype C carriage in university students for up to 2 years after the vaccination83. On the 
other hand, the carriage rate of meningococcal serogroup Y has been increasing in a cohort 
study of university students in the United Kingdom84. A carriage studies in Burkina Faso 
after 2 years of widespread use of serogroup A conjugate vaccine have shown that carriage 
of serogroup A has been nearly eliminated84. 
 
2.2.4 Recent Outbreaks of N. meningitidis in the African Meningitis Belt 
 
A total 17 outbreaks of meningococcal meningitis have been reported in countries within 
the meningitis belt of Africa who have implemented the MACV program between 2011 
and 2017. These outbreaks were reported in eight (8) countries with the total number of 





However, from 2015 to 2017, 3 to 6 outbreaks were reported per year, with almost all 
occurring during the epidemic seasons with the exception of one outbreak in a refugee 
camp in Ethiopia85. 
The country which suffered the most was Nigeria, which reported five (5) outbreaks with 
a total of 17,375 suspected cases in 55 epidemic districts. This was followed by Niger 
which had four (4) outbreaks with 9,343 cases in 21 epidemic districts. Burkina Faso 
experienced a large outbreak in 2012 with 2,372 cases in 13 epidemic districts but no 
further outbreaks were subsequently reported. One outbreak was reported in Togo in 201686 
and 2 outbreaks in 2017. Benin, Cameroun, Ethiopia and Ghana have each reported one 
outbreak within the period. The size of the outbreaks ranged from 18 cases which were 
reported in the refugee camp in Ethiopia to 14,542 cases reported in Nigeria in 2017. There 
were two outbreaks which were deemed special, where two confirmed cases in a week 
represented an epidemic. One was reported in a refugee camp in Ethiopia in 2015 and the 
other was in a prison in Cameroun in 2017. The number of reported cases in these two 
outbreaks; 18 and 25, respectively were considered the lowest within the period, with case 
fatality ratio (CFR) of 0% and 32% respectively. The average CFR for all the outbreaks 
within the period, with the exception of the two special situations, was 6% (2% - 11%). 
The total cases reported with those 17 outbreaks period constituted 45% of all cases 
reported after the introduction of MACV, ranging from 3% in 2011 to 83% in 201785. 
Serogroup C was the predominant meningococcal serogroup responsible for 11 of the 17 
outbreaks (Benin, Cameroun, Ethiopia, Niger and Nigeria) within the period, involving 78 
epidemic districts with 26,710 cases reported. Serogroup W was predominant in the other 
six (6) outbreaks (Niger in 2011, Burkina Faso, Ghana and Togo), involving 35 epidemic 
districts with 4,935 cases85. Remarkably, there were no outbreaks resulting from serogroup 
A. Although, serogroup X was not the predominant serogroup in any of the outbreaks, its 
proportion was sizeable in the outbreak in Togo in 2017, where it constituted 37% of the 








3.1 Study Population 
 
The study population included suspected cerebrospinal meningitis patients in the Northern 
zone of Ghana diagnosed within the study period. PCR confirmed results of these patients 
at the Tamale Public Health Laboratory within the study period were included in the study. 
 
3.1.1 Inclusion Criteria  
 
v Only data of suspected patients who were confirmed residents of Ghana at the time 
of the suspected disease condition were considered for the study. 
v All PCR confirmed cases of suspected cerebrospinal meningitis cases within the 
study period were included in the study.   
v  All PCR confirmed data of Neisseria meningitidis positive cases with results for 
serogroups were included in the study. 
 
3.1.2 Exclusion Criterial 
 
v Cases with incomplete data, including demographic data such as age and gender 
or sex, and or region of residence missing were excluded from the study  
v All cases which were not confirmed by PCR were excluded from the study 
v All Neisseria meningitidis positive cases without results for serogroups were also 






3.2 Study Site 
 
The study’s data were collected at the Tamale Public Health Laboratory, which is situated 
in the northern region of Ghana. The Tamale Public Health Laboratory is designated as the 
national reference laboratory for confirmatory diagnosis of cerebrospinal meningitis caused 
by bacterial pathogens in Ghana. Tamale is located in the center of the Northern Region 
with an approximated land size of 646.90180sqkm with a population of 371,351inhabitants. 
The facility is equipped with a Real-time PCR for the species and serogroups and serotypes 
identification of pathogens of bacterial meningitis. Cerebrospinal fluid (CSF) sample of all 
suspected meningitis patients from all parts of the country, especially the regions in the 
northern zone of the country which fall within Africa’s meningitis belt, are sent to the 
facility for laboratory confirmation via PCR 
3.3 Study Period 
 
The study was a retrospective study that relied on data collected over five years, spanning 
from 2016 to the first half of 2020. Complete data of all suspected cerebrospinal meningitis 
cases confirmed by PCR at the Tamale Public Health Laboratory over this period were 
collected.  
 
3.4 Sample size 
 
A predefined or calculated sample size was not set for this study. It included all reported 
cases of cerebrospinal meningitis confirmed by PCR at the Tamale Public Health 
Laboratory within the set study period. 
 






The data for this study was sourced from the Tamale Public Health Laboratory. The 
patients’ demographic data were obtained from the case investigation forms accompanying 
the cerebrospinal spinal (CSF) samples for laboratory confirmation.  
The demographic data of patients collected included age, sex and region of residence. The 
PCR confirmed laboratory data collected included results for both speciation and 
serogroups of all Neisseria meningitidis positive and speciation only for all other cases 
within the period. 
For the purposes confidentiality and security of the patients, names and epidemiological 
numbers were unlinked anonymously. The data collected was entered into a password-
protected database with access to it only by myself and my thesis supervisor. 
 
3.6 Sample Analysis for Aetiological Agents Identification 
 
3.6.1 CSF Culture 
 
Three samples of CSF of each suspected case of cerebrospinal meningitis were received at 
the Tamale Zonal Public Health Laboratory for analysis. Two, each of at least 1ml of the 
CSF in dry cryotubes and another 1ml in trans isolate (TI) medium. TI medium samples 
were used for  culture and sensitivity testing. Samples in the cryotubes were used for the 
PCR analysis and Latex Agglutination tests, Gram’s staining and physical and microscopic 
examinations. All CSF sample received were processed using standard microbiological and 
molecular techniques. 
All CSF samples for culture were inoculated on Chocolate agar, Columbia sheep blood 
agar and MacConkey agar using sterile disposable loops. The inoculums were streaked out 
on the plates and incubated at 37°C (5% CO2) for 18-24 hours. The plates were observed 
after the incubation period for bacterial growth or colony formation. Morphological 





reaction were used to categorize the bacteria into Gram positives and negatives. All Gram-
positive bacteria were identified following a biochemical chart. Optochin disc was used to 
differentiate Streptococcus pneumoniae from other alpha haemolytic streptococcus species 
which are resistant to the Optochin disc. 
 
3.6.2 Antimicrobial Susceptibility Testing. 
 
Antimicrobial susceptibility testing on all culture positive samples was performed using 
the Kirby-Bauer disc diffusion method. Pure growth of bacteria less than 24 hours old was 
used to set up the susceptibility testing. The following antibiotics were used for the 
susceptibility testing; amoxiclav (amoxicillin & clavulanic acid; 20/10µg), ceftriaxone (30 
µg), azithromycin (15 µg), amikacin (30 µg), meropenem (10 µg), 
trimethoprim/sulfamethoxazole (1.25/23.75 µg), ciprofloxacin (5 µg), gentamycin (10 µg), 
ceftazidime (30 µg) and cefotaxime (30 µg). The antibiotics were selected based on the 
CLSI guidelines.  
The testing was done by inoculating pure culture directly in 0.85% saline and adjusted to a 
turbidity of 0.5 McFarland standard. The inoculum was streaked uniformly on the entire 
plate of Mueller-Hinton agar (BD, USA) using sterile cotton buds and incubated overnight 
at 37°C. The plates were read after overnight incubation and the zone diameters interpreted 
using the zone diameter recommendation from CLSI. 
 
3.6.3 Confirmation with Real-Time PCR (rt-PCR) 
 
All the sample were confirmed using Direct Real-Time Polymerase Chain Reaction (PCR) 
technology. A triplex detection method was used for species and Streptococcus 





The serogroups of Neisseria meningitidis and Haemophilus influenzae were identified via 
monoplex detection, using FAM and ROX dyes, with the ROX as the reference dye. 
With the triplex detection, a single Master Mix was prepared and used for the simultaneous 
detection of Neisseria meningitidis, Streptococcus pneumoniae and Haemophilus 
influenzae species. The constituents of the Master Mix included; primers (both forward and 
reverse) and probes of all the species being tested in equal volumes, PCR grade water and 
Multiplex Quanta. The ratios were 12.5 µL:7.5 µL:1 µL for Master Mix, PCR grade water 
and primers and probes respectively, for a sample. 
All samples which tested positive for Neisseria meningitidis were then selected, and their 
serogroups identified using the monoplex detection method. A Master Mix was prepared 
for each of the six serogroups being tested for. Each master mix’s constituents included the 
primers (both forward and reverse) and probes of the serogroup of interest, PCR grade 
water and a monoplex Quanta with Low ROX in the same ratios as for the triplex detection. 
Reaction templates were prepared for each reaction depending on the number of samples 
being tested, and the master mix was prepared accordingly. The master mix and samples 
were added to the PCR reaction plate wells in a ratio of 23µL:2µL, respectively. The 
controls were run simultaneously with sample. However, when new dilutions of primers 
and probes were made, they were controlled before testing of patient samples. 
The prepared reaction plate with sample reagents mix was loaded into the Agilent AriaMx 
Real-Time PCR analyser for amplification and detection at a 50-cycle for a time of 
01:42:47. The cycling conditions included a first step of 95 degree Celsius for 15seconds 
and a second step of 60 degree Celsius for 1minute for the amplification segment. The 
amplification curves and Cq values for the sample at the end of the reaction cycles were 
analysed, and the results were interpreted. Samples with Cqs ≤ 34 were interpreted as 
positive, those between 34 and 35 were considered equivocal and were repeated and those 





3.7 Statistical Analysis 
 
The data collected were entered into the Statistical Package for Social Sciences (SPSS) 
software program and analysed. Differences between discrete variables were analyzed 
using Jonckheere-Terpstra Non-Parametric Test. A p-value <0.05 was considered 
statistically significant 
 
3.8 Ethical Consideration 
 
The study’s ethical approval was obtained from the Yonsei University’s Institutional 
Review Board (IRB) of Severance Hospital with the approval number IRB No: Y-2020-
0105. Permission was also obtained from the Ghana Health Service Northern Regional 
Directorate to use the data on meningitis from the Public Health Laboratory of the region 









4.1 General and Sociodemographic Characteristics of the study population 
 
A total of 2426 suspected cases were included in the study. Of this number, 236, 747, 538, 
634 and 271 were tested in 2016, 2017, 2018, 2019 and 2020 respectively. 
Of the total number tested within the study period, 52.6% were males and 47.4% were 
female (as shown in Table 1). Regarding the regional distributions, 44.4% were from the 
Upper West region, 37.0% from the Northern region, 12.2% from the Upper east region, 
6% from the Brong Ahafo Region (Bono East, Ahafo and Bono) and 0.3% from the Ashanti 
region (shown in Table 1). Concerning the age-group distribution, of all the suspected 
cases, 2.9% were under the age of one year, 4.9%, 9.8%, 12.7%, 13.4%, 18.3%, 
18.4% and 19.5% were within the age groups; 65years and older, 45-64years, 1-
4years, 11-15years, 5-10years, 24-44years and 16-23years, respectively (as shown 
Table 1). 
 
4.2 All Suspected Cases by Causal or Aetiological Agents of Bacterial Meningitis 
 
Of the total suspected cases, 63.4% were negative for all the aetiological agents tested for 
by PCR (as shown in table 1). 19.1%, 16.3% 1.2% and approximately 0.0% tested positive 
for Streptococcus pneumoniae, Neisseria meningitidis, Haemophilus influenzae and 








Table1: Sociodemographic distribution and aetiological agents of all suspected cases 
of bacterial cerebrospinal meningitis (CSM) cases confirmed by Polymerase Chain 














 n (%) n (%) n (%) n (%) n (%) n (%) 
Aetiological 






94(39.3) 120 (16.1) 59 (11.0) 56 (8.8) 66 (24.4) 395 (16.3) 
51(21.6) 159 (21.3) 100 (18.6) 96 (15.1) 57 (21.0) 463 (19.1) 
3 (1.3) 8 (1.1) 8 (1.5) 4 (0.6) 5 (1.8) 28 (1.2) 
0 (0.0) 0 (0.0) 1 (0.2) 0 (0.0) 0 (0.0) 1(0.0) 
88 (37.3) 460 (61.6) 370 (68.8) 478 
(75.4) 




      
Under 1 4 (1.7) 29 (3.9) 16 (3.0) 19 (3.0) 3 (1.1) 71 (2.9) 
1-4 41 (17.4) 113 (15.1) 62 (11.5) 54 (8.5) 37 (13.7) 307 (12.7) 
5-10 53 (22.5) 145 (19.4) 90 (16.7) 99 (15.6) 58 (21.4) 445 (18.3) 
11-15 35 (14.8) 98 (13.1) 63 (11.7) 80 (12.6) 49 (18.1) 325 (13.4) 
16-23 48 (20.3) 140 (18.7) 108 (20.1) 130 
(20.5) 
48 (17.7) 474 (19.5) 
24-44 34 (14.4) 123 (16.5) 116 (21.6) 125 
(19.7) 
48 (17.7) 446 (18.4) 
45-64 17 (7.2) 58 (7.8) 52 (9.7) 91 (14.4) 20 (7.4) 238 (9.8) 





Regions       
Ashanti 0 (0.0) 8 (1.1) 0 (0.0) 0 (0.0) 0 (0.0) 8 (0.3) 
Brong Ahafo 0 (0.0) 54 (7.2) 0 (0.0) 69 (10.9) 9 (3.3) 132 (5.4) 
Bono East 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 10 (3.7) 10 (0.4) 
Bono 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 5 (1.8) 5 (0.2) 
Northern 122 (51.7) 265 (35.5) 204 (37.9) 210 
(33.1) 
97 (35.8) 898 (37.0) 
Upper East 57 (24.2) 90 (12.0) 57 (10.6) 74 (11.7) 17 (6.3) 295 (12.2) 
Upper West 57 (24.2) 330 (44.2) 277 (51.5) 281 
(44.3) 
133 (49.1) 1078 
(44.4) 
Sex/Gender       
Male 127 (53.8) 412 (55.2) 274 (50.9) 315 
(49.7) 
147 (54.2) 1275 
(52.6) 
Female 109 (46.2) 335 (44.8) 264 (49.1) 319 
(50.3) 
124 (45.8) 1151 
(47.4) 













Table 2: Sociodemographic Distribution of the various serogroups of Neisseria 














 n (%) n (%) n (%) n (%) n (%) n (%) 
Regions   
Brong Ahafo 0 (0.0) 0 (0.0) 0 (0.0) 5 (1.8) 0 (0.0) 5 (1.3) 
Northern 1 (50.0) 0 (0.0) 6 (50.0) 183 (64.9) 15 (15.5) 205 (51.9) 
Upper East 0 (0.0) 0 (0.0) 3 (25.0) 40 (14.2) 40 (41.2) 83 (21.0) 
Upper West 1 (50.0) 2 (100.0) 3 (25.0) 54 (19.1) 42 (43.3) 102 (25.8) 
Age Group       
Under 1 0 (0.0) 0 (0.0) 0 (0.0) 8 (2.8) 0 (0.0) 8 (2.0) 
1-4 0 (0.0) 0 (0.0) 1 (8.3) 58 (20.6) 9 (9.3) 68 (17.2) 
5-10 0 (0.0) 1 (50.0) 4 (33.3) 82 (29.1) 44 (45.4) 131 (33.2) 
11-15 1 (50.0) 0 (0.0) 4 (33.3) 50 (17.7) 23 (23.7) 78 (19.7) 
16-23 1 (50.0) 1 (50.0) 1 (8.3) 56 (19.9) 15 (15.5) 74 (18.7) 
24-44 0 (0.0) 0 (0.0) 2 (16.7) 18 (6.4) 3 (3.1) 23 (5.8) 
45-64 (0.0) 0 (0.0) 0 (0.0) 10 (3.5) 3 (3.1) 13 (3.3) 
Sex/Gender  
Male  1 (50.0) 2 (100.0) 7 (58.3) 156 (55.3) 57 (58.8) 223 (56.5) 
Female  1 (50.0) 0 (0.0) 5 (41.7) 126 (44.7) 40 (41.2) 172 (43.5) 







4.3 Sociodemographic Effect and serogroup Distribution  
 
Of the 395 cases tested positive for Neisseria meningitidis, 282, 97, 12, 2,2 were for 
serogroups W, X, NG, B and C, respectively (as shown in Table 2). Of the total, 56.5% 
were males and 43.5% were females. 51.9%, 25.8%, 21.0% and 1.3% of the Neisseria 
meningitidis cases were from the Northern region, Upper West region, Upper East region 
and the Brong Ahafo region respectively. With respect to the age group distributions, 
33.2%, 19.7%, 18.7%, 17.2%, 5.8%, 3.3% and 2.0% were in the age groups, 5-10years, 11-
15years, 16-23years, 1-4years, 24-44years, 45-64yeas and under 1 year respectively (as 
shown in table 2). 
Table 3: Distribution/Trend of the various Neisseria meningitidis serogroups 

















n (%) n (%) n (%) n (%) n (%) n (%) p-
valu
e 
 B 0 (0.0) 1 (0.8) 1 (1.7) 0 (0.0) 0 (0.0) 2 (0.5) 0.78 
C 1 (1.1) 1 (0.8) 0 (0.0) 0 (0.0) 0 (0.0) 2 (0.5) 0.05 
NG 0 (0.0) 0 (0.0) 5 (8.5) 5 (8.9) 2 (3.0) 12 (3.0) 0.21 

















Figure 3: Trends in Neisseria meningitidis serogroup 
 
4.4 Yearly Trend in Neisseria Meningitidis Serogroups from 2016-March 
2020 
 
There is a significant upward trend of serogroup X (p=0.01) and downward trend of the 
serogroup W (p=0.01) and serogroup C (0.05). The serogroup B is also showing a 
downward trend and the NG serogroups are in the upward trajectory. However, the yearly 
changes in the serogroups; B and NG are insignificant as shown in table 3 (with p-values; 









Tables 4: Distribution/Trend of the various Neisseria meningitidis serogroups 

















serogroup n (%) n (%) n (%) n (%) n (%) n (%) p-value 
Under 1 W 2(100.0) 2(100.0) 3(100.0) 1(100.0)  8(100.0) 0.16 
1-4 
 





6 (75.0) 5 
(100.0) 
1 (11.1) 58 
(85.3) 
0.16 
X 0 (0.0) 0 (0.0) 2 (25.0) 0 (0.0) 7 (77.8) 9 (13.2) 0.17 
5-10 
 
C 1 (4.2) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.8) 0.16 
NG 0 (0.0) 0 (0.0) 2 (10.0) 1 (6.7) 1 (3.7) 4 (3.1) 0.45 
W 22 (91.7) 44 
(97.8) 
10 (50.0) 4 (26.7) 2 (7.4) 82 
(62.6) 
0.05 
X 1 (4.2) 1 (2.2) 8 (40.0) 10 
(66.7) 





B 0 (0.0) 1 (5.3) 0 (0.0) 0 (0.0) 0 (0.0) 1 (1.3) 0.48 





7 (58.3) 6 (46.2) 3 (16.7) 50 
(64.1) 
0.01 





B 0 (0.0) 0 (0.0) 1 (7.7) 0 (0.0) 0 (0.0) 1 (1.4) 1.00 
C 0 (0.0) 1 (4.5) 0 (0.0) 0 (0.0) 0 (0.0) 1 (1.4) 0.48 









9 (69.2) 7 (50.0) 3 (37.5) 56 
(75.7) 
0.01 





NG 0 (0.0) 0 (0.0) 1 (50.0) 1 (25.0) 0 (0.0) 2 (8.7) 0.78 
W 9 (100.0) 5 
(100.0) 
1 (50.0) 2 (50.0) 1 (33.3) 18 
(78.3) 
0.04 
X 0 (0.0) 0 (0.0) 0 (0.0) 1 (25.0) 2 (66.7) 3 (13.0) 0.05 
45-64 
 
W 5 (100.0) 2 
(100.0) 
0 (0.0) 3 (75.0) 0 (0.0) 10 
(76.9) 
0.12 
X 0 (0.0) 0 (0.0) 1 (100.0) 1 (25.0) 1 (100.0) 3 (23.1) 0.12 







Figure 4: N. meningitidis Serogroups trends in Different Age Group (2016-2020) 
 
4.5 Serogroup Trends In Different Age Group 
 
In 2016 (as shown in Table 4), all the Neisseria meningitidis cases within the age groups 
under1 year and 1-4years were serogroup W. In the age group, 5-10years, 91.7%, 4.2% and 
4.2% of the cases were serogroups, W, X and C respectively. For the age groups 11-
15years, 16-23years, 24-44years and 45-64years, 100% of the cases were serogroup W 
respectively. In 2017, 100% of cases within the age groups, 1-4years, 24-44years, 45-
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97.8% of cases were serogroup W and 2.2%, serogroup X. 94.7% and 90.9% of cases in 
age group 11-15years and 16-23years, respectively were serogroup W and 5.3% and 4.5% 
for serogroups B and X respectively. Of the total cases in 2018, 8 cases were for people 
within the age group 1-4, of which 75% were serogroup W and 25% were serogroup X. 3 
cases were for the age group under 1year of which all were serogroup W. 50%, 40% and 
10% were serogroups W, X and NG respectively for 5-10years age group. As can be seen 
from Table 4, there have been downward and upward trends of serogroups B, C, W and 
NG, and the serogroup X respectively. However, the yearly changes of the serogroups B, 
C, and NG were insignificant across all age groups. The yearly changes of the serogroup 
W, however, are significant across almost age groups, and that of the serogroup X was 
significant in only the age groups; 5-10years, 11-15years, 16-23years and 24-44years. 
 
Table 5: Distribution/Trend of the various Neisseria meningitidis serogroups 
confirmed by PCR by Region of residence year. 















n (%) n (%) n (%) n (%) n (%) n (%) p-value 
Brong 
Ahafo 
W  4 (100.0)  1 (100.0)  5 (100.0) 
1.00 
Northern B 0 (0.0) 0 (0.0) 1 (3.2) 0 (0.0) 0 (0.0) 1 (0.5) 1.00 
NG 0 (0.0) 0 (0.0) 4 (12.9) 2 (11.1) 0 (0.0) 6 (2.9) 0.78 
W 59 
(100.0) 
77 (97.5) 23 
(74.2) 
15 (83.3) 9 (50.0) 183 
(89.3) 
0.05 
X 0 (0.0) 2 (2.5) 3 (9.7) 1 (5.6) 9 (50.0) 15 (7.3) 0.05 





W 14 (93.3) 24 
(100.0) 
1 (7.7) 1 (3.8) 0 (0.0) 40 
(48.2) 
0.05 
X 1 (6.7) 0 (0.0) 12 
(92.3) 







B 0 (0.0) 1 (7.7) 0 (0.0) 0 (0.0) 0 (0.00 1 (1.0) 0.48 
C 1 (5.0) 1 (7.7) 0 (0.0) 0 (0.0) 0 (0.0) 2 (2.0) 0.16 
NG 0 (0.0) 0 (0.0) 1 (6.7) 0 (0.0) 2 (4.7) 3 (2.9) 0.41 




1 (2.3) 54 
(52.9) 
0.33 





B, C, W and X- Neisseria meningitidis Serogroups B, C, W and X, respectively. NG-
Non-groupable serogroups 
 
4.6 Regional Trends of Serogroups 
 
In 2016, 100%, 93% and 95% of positive cases recorded in the Northern, Upper East and 
Upper West regions respective were serogroup W (as shown in Table 5). In 2017, 100%, 
all the cases in Upper East and Brong Ahafo regions were serogroup W. 97.5%, and 84.6% 
of the cases in Northern and Upper West regions respectively, were also serogroup W. 
From 2018-2020, however, except the Northern region in 2018 (74.2%), Brong Ahafo and 
Upper West regions in 2019 (100%) where a more significant percentage of the cases were 
serogroup W, the rest have more significant percentage of the cases being serogroup X (as 
shown in Table 5). Although, the serogroups Wand X are showing downward and upward 
trends, respectively, across all the reporting regions, their yearly changes are only 





Table 6: Distribution/Trend of the various Neisseria meningitidis serogroups 
confirmed by PCR by Sex/Gender and year 
B, C, W and X- Neisseria meningitidis Serogroups B, C, W and X, respectively. NG-
Non-groupable serogroups 
 
4.7 Trends of Serogroups in the various Sex groups 
 
100% of cases in females and 96.2% of cases in males were serogroup W in 2016. 97.0% 
and 96.3% of the cases in males and females, respectively, in 2017 were serogroup W. The 














Sex Serogroups  n (%) n (%) n (%) n (%) n (%) n (%) p-
value 
Male B 0 (0.0) 1 (1.5) 0 (0.0) 0 (0.00 0 (0.0) 1 (0.4) 0.48 
C 1 (1.9) 1 (1.5) 0 (0.0) 0 (0.0) 0 (0.0) 2 (0.9) 0.05 
NG 0 (0.0) 0 (0.0) 4 (11.4) 2 (6.7) 1 (2.5) 7 (3.1) 0.45 






5 (12.5) 156 
(70.0) 
0.14 






57 (25.6) 0.14 
Female B 0 (0.0) 0 (0.0) 1 (4.2) 0 (0.0) 0 (0.0) 1 (0.6) 1.00 









5 (19.2) 126 
(73.3) 
0.01 









respectively, in 2018. In 2019, in the male group, 60% of the cases were serogroup W and 
33.3% and 6.7%were serogroup X and NG, respectively. However, in the same year, 50% 
of the cases in the female group were serogroup X and 38.5% and 11.5% were serogroups 
W and NG, respectively. Finally, 85% and 76.9% of cases in males and females, 
respectively, in 2020 were serogroup X. Although there has been a downward trend of 
serogroup W and upward trend of the serogroup X in both males and females, the yearly 





















Cerebrospinal meningitis (CSM) due to Neisseria meningitidis is a contagious disease. 
Viesseux  gave the foremost vivid account of CSM outbreak in 1806 following a classical 
epidemic in Geneva, Switzerland87. Neisseria meningitidis meningitis epidemic is a very 
serious medical emergency with public health and socioeconomic implications. Neisseria 
meningitidis was first defined in 188488, and isolated from cerebrospinal meningitis patients 
by Weichselbaum in Vienna in 1887 as a gram negative diplococci. Based on the 
antigenicity of its capsular polysaccharides, it was classified into thirteen serogroups89, 
including A, B, C,D, H, I, K, L, W135, X,Y, Z, Z` with 90% of invasive cases caused by 
serogroups A, B and C. Traditionally, Y and W135 occasionally caused diseases, however, 
since the year 2000, outbreaks and sometimes epidemics are the results of W13590-93. 
Epidemics of meningitis due to Neisseria meningitidis are often difficult to predict, usually 
leading to delayed initiation of control measures such as immunization, resulting in poor 
outcome87. 
Therefore, this reports establishes a five-year trend of cerebrospinal meningitis causing 
Neisseria meningitidis serogroups in Ghana’s meningitis belt. The study reports 16.3% 
(395/2426) of all suspected cases of cerebrospinal meningitis and as high as 44.5% 
(395/887) of all confirmed positive CSM cases by real-time PCR at the Tamale Public 
Health Laboratory within the study period to be caused by various serogroups of Neisseria 
meningitidis.  
Generally, the study found out that since the outbreak of serogroup W in Ghana in 2016, 
cases of meningitis due Neisseria meningitidis had been on the downward trajectory until 
2020 where there was a marginal spike in the number of cases resulting from an outbreak 
(16.1%, 11.0%, 8.8% and 24.4% for 2017, 2018, 2019 and 2020 respectively). The general 





explained by the 2016 massive reactive vaccination campaign with meningococcal 
polysaccharide ACW vaccine following the outbreak serogroup W in 201638. With this, it 
was expected that some immunity would be achieved leading to a reduction of the yearly 
cases of meningitis due to Neisseria meningitidis serogroup W. Since serogroup W 
constitutes a larger percentage of cases due Neisseria meningitidis, you would expect that 
the overall cases due Neisseria meningitidis would decline. The increase in the number of 
cases in 2020 was however due to the recently reported outbreak resulting from a non-
vaccine type serogroup. 
The study reports significant yearly changes of both serogroups W (p=0.01) and serogroup 
X (p=0.01) over the five years. Although, the serogroup W, though saw a little increase in 
the number of cases in 2017 as compared to that in 2016, it has been on a downward trend 
(Std. J-T statistic= -2.45) since then, accounting for only 15.2% of total Neisseria 
meningitidis cases in the year, 2020, as against 96.7% in 2017. The serogroup X, however, 
has consistently been on the upward trajectory (Std. J-T statistic= 2.45) since 2016, making 
up 81.8% of the total Neisseria meningitidis cases in 2020 as against 1.1% in 2016. This 
finding by the current study is consistent with a recent nine-year study which was carried 
out in 2019 in Niger to establish the epidemiology of bacterial meningitis since the 
introduction of the meningococcal serogroup A conjugate vaccine. A similar trajectory of 
the serogroups W and X as the current study was established by that study94. 
However, the trends exhibited by these two serogroup (W and X) do not come as a surprise. 
There was a reactive vaccination campaign of meningococcal polysaccharide ACW 
vaccine in the districts affected by the 2016 Neisseria meningitidis serogroup W38 outbreak, 
so it was expected that some population immunity would be achieved and result in 
reduction in the number of cases due to serogroup W Neisseria meningitidis as time goes 
by. The downward trend of the serogroup W from 2017 to 2020 is therefore, attributable to 
population immunity resulting from the vaccination campaign and community education 





Of note, however, is that, unlike serogroup A which was eliminated in the country just 
about two (2) years after the introduction of the monovalent meningococcal A conjugate 
vaccine, there is still the  persistence of serogroup W, even four (4) years after the 
vaccination campaign of the polysaccharide meningococcal ACW vaccine, though the 
coverage rates for both campaigns were the same (98% for the monovalent meningococcal 
A conjugate vaccine in 2012 and over 98% for the polysaccharide meningococcal ACW 
vaccine in 2016)95, 96. This phenomenon may be explained by the relative effectiveness of 
conjugate and polysaccharide vaccines. Both have been demonstrated to be effective. 
However, most polysaccharide vaccine induce hyporesponsiveness and are less 
immunogenic in children under 2years and are unable to induce immunologic memory and 
affinity maturation in older children and adults as compared to conjugate vaccines97, 98.  
Moreover, it must be noted that, unlike the meningococcal A vaccine, which had since 2016 
been incorporated into the routine vaccination program in the country, the polysaccharide 
meningococcal ACW is still not incorporated into the routine vaccination program. This, I 
believe, may have led to dilution of herd immunity resulting from birth and immigration 
due to the lack of an ongoing vaccination program. Hence the persistence of the serogroup 
W, though, a decline in numbers. The lack of continuous vaccination or its incorporation 
into the routine vaccination program could also lead to future epidemics resulting from the 
same serogroup as immunity of the sensitized or vaccinated wanes. Therefore, it is 
necessary that it is incorporated into the routine vaccination program to prevent future 
epidemics. 
However, the upward trend of the serogroup X maybe attributable to the unavailability of 
vaccine program, coupled with highly unsensitized or susceptible population. The 
emergence of the serogroup X as the predominant aetiological agent in the wake of 
declining serogroup W in Ghana also reflects past situations wherein the wake of the 
decline of a previously predominant serogroup is the emergence of a different serogroup 
as the predominant aetiological agent. For instance, the emergence of serogroup W in 2012, 





conjugate vaccine in Burkina Faso, Mali and Niger in 201023-25. Moreover, a study reports 
that a sizeable proportion of serogroup X during the 2017 outbreak in Togo where it 
constituted 37% of the cases85. However, unlike the recent outbreak in Ghana, which this 
study reports, where the serogroup X is the predominant (81.1%) agent, it was not the 
predominant aetiological meningococcal agent. 
The serogroups B and non-groupable serogroups have largely remain stable over the study 
period. The significant (p=0.05) dwindling or downward trend (Std. J-T statistic= -1.94) of 
the serogroup C may also be explained by the vaccine availability. However, declining 
cases of serogroup B, even in the absence of vaccine intervention, corroborate a systematic 
review study which reports an overall decreasing trend, of Neisseria meningitidis serogroup 
B, particularly in countries where data collection had been consistent99. The number of the 
non-groupable serogroups has increased in 2018 and 2019 and declined slightly in the year 
2020. These changes in the non-groupable serogroups across the years has however not 
been significant (p=0.29). 
The distribution of the various serogroups in the different ages groups also follow the same 
trend as the cumulative cases. There is a downward trend of the serogroup W across all age 
groups considered in this study. Except for those under 1 year of age, where there was no 
reported case of serogroup X, it has been on the upward trajectory across all other age 
groups considered in this study. However, though there have been changes in the numbers 
of cases in both serogroups across all age groups across the years under study, significant 
changes in both serogroups were only seen in the age groups; 5-10years (p=0.05 and 0.05), 
16-23years (p=0.01 and 0.01) and 24-44 years (0.04 and 0.05), for the serogroups W and 
X respectively. Also, consistent with a study carried out in Niger in 2019 (4.2%)94, cases 
of Neisseria meningitidis are uncommon among children under 1year in the current study 
(2.0%), and all the cases in this age bracket in this study were caused be serogroup W. 
Except serogroup B, this study finds that cases of all the other serogroups considered in the 





(5-10years) constitute 33% of cases of Neisseria meningitidis in this study. However, 
majority (75.8%) of cases in the Niger study, were found in the age group, 1-14yeays94. 
This study’s gender distribution also follows the general trend, as described in Table 3 in 
the results section. However, significant changes across the years in both serogroup W and 
X were only seen in the female group, p=0.01 and 0.01, for serogroups W and X 
respectively. There is, however, no significant change in any of the serogroups in the male 
category. 
Geographically, both serogroup W and X across all reporting regions in this study follow 
the same pattern as the cumulative cases. There is an increasing number of cases of 
serogroup X across all the regions in the wake of serogroup W decline also across all the 
regions. However, until 2018, the Upper West region which has recorded the highest 
number of cases of serogroup X in the current outbreak in Ghana, had not recorded cases 
of serogroup X in the recent past. Therefore, it is understandable that it experienced the 
outbreak since the population may have been naïve immunologically to the Neisseria 
meningitidis serogroup X. However, the Northern and the Upper East regions have 
consistently had cases of serogroup X since 2017. Before 2020, the Upper East region had 
been the region with predominant serogroup X cases. Cases of serogroup W are however, 
predominantly in the Northern region across all the years under study. The yearly changes 
of both serogroups were only significant (p= 0.05 for both serogroups) in the Northern 
region. However, the serogroup W changes were also significant (p=0.05) in the Upper 
East Region 
Although there is currently no licenced vaccine targeting serogroup X available in the 
country and the region as whole in the wake of the rise into dominance of Neisseria 
meningitidis X in Ghana, a pentavalent meningococcal conjugate vaccine (MenACWXY) 
is under development for use in the African region is expected to be licenced in the year, 
2021100, 101. It is therefore recommended that the country positions itself well by identifying 





procured for use immediately, and in the interim, case-based surveillance and community 
sensitization should be intensified across all regions within the meningitis belt of the 
country. It is also recommended that robust surveillance is instituted for all the other non-
vaccine type and the non-groupable serogroups so that an emerging threat from any is 
identified from the onset. Capacity for testing should also be built for all regions within the 
‘meningitis belt’ of the country to aid rapid testing. A molecular epidemiology of the 
serogroup X is recommended to determine whether the strains in circulation are the same 




In conclusion, the results of the analysis of the cases of bacterial meningitis due to Neisseria 
meningitidis from 2016 to 2020 shows an emergence of serogroup X, a non-vaccine type 
Neisseria meningitidis serogroup, as the predominant Neisseria meningitidis serogroup, 
and is on the upward trajectory since 2016 in the wake of a declining serogroup W after the 
introduction of the meningococcal polysaccharide ACW vaccine following the outbreak of 
serogroup W in the Upper West region in 2016. However, unlike serogroup A which has 
had no case recorded since 2014 after the introduction of meningococcal A conjugate 
vaccine in 2012, the serogroup W persists, even four (4) years after the meningococcal 
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